Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...189190191192193194195196197198199...10661067»
  • ||||||||||  Xhance (fluticasone propionate intranasal spray) / OptiNose
    Trial completion date, Trial primary completion date:  OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps (clinicaltrials.gov) -  Mar 23, 2023   
    P3,  N=120, Recruiting, 
    Further trials are warranted to establish clinical efficacy, optimal timing and duration of interventions for SAM. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  midodrine hydrochloride / Generic mfg.
    Midodrine for the early liberation from vasopressor support in the icu  () -  Mar 23, 2023 - Abstract #ISICEM2023ISICEM_1212;    
    Treatment interventions measured included invasive mechanical ventilation (72.7% and 75.0%), CRRT (9.1% and 12.5%), IV hydrocortisone (36.4% and 37.5%) and blood products (45.4% and 37.5%). This pilot study provides evidence that recruitment into a larger multi-site RCT is feasible to evaluate the role of midoddrine in earlier liberation from IV vasopressor therapy.
  • ||||||||||  Who is in my brain? () -  Mar 23, 2023 - Abstract #ISICEM2023ISICEM_1136;    
    Early diagnosis, neuroprotective management and effective treatment improve prognosis. Recently, miltefosine is proved) to be effective.
  • ||||||||||  dexamethasone / Generic mfg.
    Risk factors for nosocomial infections in covid-19 icu population () -  Mar 23, 2023 - Abstract #ISICEM2023ISICEM_1074;    
    We identified prolonged deep sedation, corticosteroids use and patient characteristics (CAD, obesity, CLD, older age) as independent risk factors for NI development in COVID-19 critically ill patients. It is also noteworthy to point out for the presence of confounding variables, including the excessive workload in the ICU during this period, leading to an increase in NI numbers.
  • ||||||||||  dexamethasone / Generic mfg.
    Dexamethasone (Twitter) -  Mar 22, 2023   
  • ||||||||||  lulizumab pegol (BMS-931699) / BMS
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  Selective CD28 Blockade in Renal Transplant Recipients (clinicaltrials.gov) -  Mar 22, 2023   
    P2,  N=0, Withdrawn, 
    Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Jun 2024 N=54 --> 0 | Trial completion date: Oct 2024 --> Sep 2022 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2023 --> Sep 2022
  • ||||||||||  Clinical data, Journal:  Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: results from the BCH-LCH 2014 protocol study. (Pubmed Central) -  Mar 21, 2023   
    One hundred thirty-nine patients who lacked a response to initial treatment were shifted to second-line therapy, 72 to intensive treatment Arm S1 (a combination of cytarabine, cladribine, vindesine, and dexamethasone), and 67 to Arm S2 (without cladribine)...Multivariate analysis revealed that early treatment response, the involvement of RO, skin, and oral mucosa, as well as laboratory parameters, including CRP and ?-GT, were independent risk factors for PFS of LCH. Thus, the prognosis of LCH in children has been improved significantly with stratified chemotherapy, and progression and relapse remained the challenges, especially for RO+ patients.
  • ||||||||||  triamcinolone acetonide / Generic mfg.
    Journal:  Intralesional steroid injections for inflammatory nail dystrophies in the pediatric population. (Pubmed Central) -  Mar 21, 2023   
    Intralesional injections of triamcinolone acetonide are widely used to successfully treat several inflammatory nail conditions...Our report shows how this procedure is feasible and successful in children, even without a digital block. The step-by-step technique and tips to reduce pain should encourage clinicians to offer it as an alternative option to children with inflammatory nail disorders.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Pregnancy and COVID-19: past, present and future. (Pubmed Central) -  Mar 21, 2023   
    The management of pregnant women with coronavirus disease 2019 (COVID-19) is similar to that of non-pregnant women, and effective treatments, including antiviral therapy, dexamethasone, and prophylactic anticoagulation should not be withheld during pregnancy...In order to prepare for future pandemics, it is necessary to apply lessons learned from this pandemic. Policymakers and healthcare leaders must determine efficient and effective strategies for preserving safe maternal care, even during an ongoing global emergency.
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Journal:  Prophylactic Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Embolization of Renal Angiomyolipoma: A Comparative Study. (Pubmed Central) -  Mar 21, 2023   
    The prophylactic steroid protocol used in the study was as follows: 250 mg of intravenous methylprednisolone (Solu-Medrol) 2 h before the RAE procedure, followed by 2 days of intravenous prednisolone (Predonine; 2 mg/kg/day), which was tapered by halving the dose every 2 days within the course of 2 weeks...Conversely, the median length of hospital stay was not significantly shorter in the steroid group (P = 0.292). The prophylactic use of steroids before and after embolization of renal AML may be effective in preventing PES in this small retrospective study.
  • ||||||||||  prednisone / Generic mfg., mycophenolate mofetil / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
    Journal:  Tuberculosis remains a major burden in systemic lupus erythematosus patients in Durban, South Africa. (Pubmed Central) -  Mar 21, 2023   
    The EPTB patients also had increase in features of disease activity (renal, thrombocytopenia, ds-DNA antibodies), and increase in ever use of intravenous methylprednisolone (IV-MP) and mycophenolate mofetil (MMF)...We show an increased prevalence of TB (14.1%) and EPTB (58.3%) in SLE in an endemic area and confirm that features of disease activity and use of immunosuppressive therapy are the major risk factors. Renal involvement (as a cumulative criterion) is an independent risk factor for EPTB.
  • ||||||||||  budesonide / Generic mfg.
    Review, Journal:  Pathophysiology and clinical manifestations of immune complex vasculitides. (Pubmed Central) -  Mar 21, 2023   
    Our knowledge of distinct forms and different pathophysiological pathways of IC vasculitides may lead to in efficacious or targeted therapies. Antibodies to complement components or intestinal budesonide for IgAV are promising agents (the latter suppresses the pathophysiologically related IgA nephropathy by reducing the generation of mucosal IgA.